These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

840 related articles for article (PubMed ID: 30045977)

  • 21. LRRK2 and Parkinson's Disease: From Lack of Structure to Gain of Function.
    Blanca Ramírez M; Madero-Perez J; Rivero-Rios P; Martinez-Salvador M; Lara Ordonez AJ; Fernandez B; Fdez E; Hilfiker S
    Curr Protein Pept Sci; 2017; 18(7):677-686. PubMed ID: 26965688
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mitochondrial Calcium Dysregulation Contributes to Dendrite Degeneration Mediated by PD/LBD-Associated LRRK2 Mutants.
    Verma M; Callio J; Otero PA; Sekler I; Wills ZP; Chu CT
    J Neurosci; 2017 Nov; 37(46):11151-11165. PubMed ID: 29038245
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Upregulation of the p53-p21 pathway by G2019S LRRK2 contributes to the cellular senescence and accumulation of α-synuclein.
    Ho DH; Seol W; Son I
    Cell Cycle; 2019 Feb; 18(4):467-475. PubMed ID: 30712480
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Kinase activity of mutant LRRK2 manifests differently in hetero-dimeric vs. homo-dimeric complexes.
    Leandrou E; Markidi E; Memou A; Melachroinou K; Greggio E; Rideout HJ
    Biochem J; 2019 Feb; 476(3):559-579. PubMed ID: 30670570
    [TBL] [Abstract][Full Text] [Related]  

  • 25. LRRK2 and Proteostasis in Parkinson's Disease.
    Pérez-Carrión MD; Posadas I; Solera J; Ceña V
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743250
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Accumulation of mitochondrial 7S DNA in idiopathic and LRRK2 associated Parkinson's disease.
    Podlesniy P; Puigròs M; Serra N; Fernández-Santiago R; Ezquerra M; Tolosa E; Trullas R
    EBioMedicine; 2019 Oct; 48():554-567. PubMed ID: 31631040
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Parkinson's disease-associated mutant LRRK2 phosphorylates Rab7L1 and modifies trans-Golgi morphology.
    Fujimoto T; Kuwahara T; Eguchi T; Sakurai M; Komori T; Iwatsubo T
    Biochem Biophys Res Commun; 2018 Jan; 495(2):1708-1715. PubMed ID: 29223392
    [TBL] [Abstract][Full Text] [Related]  

  • 28. LRRK2 levels and phosphorylation in Parkinson's disease brain and cases with restricted Lewy bodies.
    Dzamko N; Gysbers AM; Bandopadhyay R; Bolliger MF; Uchino A; Zhao Y; Takao M; Wauters S; van de Berg WD; Takahashi-Fujigasaki J; Nichols RJ; Holton JL; Murayama S; Halliday GM
    Mov Disord; 2017 Mar; 32(3):423-432. PubMed ID: 27911006
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls.
    Agalliu I; Ortega RA; Luciano MS; Mirelman A; Pont-Sunyer C; Brockmann K; Vilas D; Tolosa E; Berg D; Warø B; Glickman A; Raymond D; Inzelberg R; Ruiz-Martinez J; Mondragon E; Friedman E; Hassin-Baer S; Alcalay RN; Mejia-Santana H; Aasly J; Foroud T; Marder K; Giladi N; Bressman S; Saunders-Pullman R
    Mov Disord; 2019 Sep; 34(9):1392-1398. PubMed ID: 31348549
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cerebrospinal fluid biomarkers and clinical features in leucine-rich repeat kinase 2 (LRRK2) mutation carriers.
    Vilas D; Shaw LM; Taylor P; Berg D; Brockmann K; Aasly J; Marras C; Pont-Sunyer C; Ríos J; Marek K; Tolosa E
    Mov Disord; 2016 Jun; 31(6):906-14. PubMed ID: 27041685
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alzheimer's disease tau is a prominent pathology in LRRK2 Parkinson's disease.
    Henderson MX; Sengupta M; Trojanowski JQ; Lee VMY
    Acta Neuropathol Commun; 2019 Nov; 7(1):183. PubMed ID: 31733655
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The LRRK2 kinase substrates RAB8a and RAB10 contribute complementary but distinct disease-relevant phenotypes in human neurons.
    Mamais A; Sanyal A; Fajfer A; Zykoski CG; Guldin M; Riley-DiPaolo A; Subrahmanian N; Gibbs W; Lin S; LaVoie MJ
    Stem Cell Reports; 2024 Feb; 19(2):163-173. PubMed ID: 38307024
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
    Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
    Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
    [TBL] [Abstract][Full Text] [Related]  

  • 34. LRRK2 kinase inhibitors reduce alpha-synuclein in human neuronal cell lines with the G2019S mutation.
    Zhao Y; Keshiya S; Perera G; Schramko L; Halliday GM; Dzamko N
    Neurobiol Dis; 2020 Oct; 144():105049. PubMed ID: 32800998
    [TBL] [Abstract][Full Text] [Related]  

  • 35. LRRK2 inhibition does not impart protection from α-synuclein pathology and neuron death in non-transgenic mice.
    Henderson MX; Sengupta M; McGeary I; Zhang B; Olufemi MF; Brown H; Trojanowski JQ; Lee VMY
    Acta Neuropathol Commun; 2019 Feb; 7(1):28. PubMed ID: 30808409
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dysregulated phosphorylation of Rab GTPases by LRRK2 induces neurodegeneration.
    Jeong GR; Jang EH; Bae JR; Jun S; Kang HC; Park CH; Shin JH; Yamamoto Y; Tanaka-Yamamoto K; Dawson VL; Dawson TM; Hur EM; Lee BD
    Mol Neurodegener; 2018 Feb; 13(1):8. PubMed ID: 29439717
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Divergent Effects of G2019S and R1441C LRRK2 Mutations on LRRK2 and Rab10 Phosphorylations in Mouse Tissues.
    Iannotta L; Biosa A; Kluss JH; Tombesi G; Kaganovich A; Cogo S; Plotegher N; Civiero L; Lobbestael E; Baekelandt V; Cookson MR; Greggio E
    Cells; 2020 Oct; 9(11):. PubMed ID: 33105882
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lysosomal Pathogenesis of Parkinson's Disease: Insights From LRRK2 and GBA1 Rodent Models.
    Volta M
    Neurotherapeutics; 2023 Jan; 20(1):127-139. PubMed ID: 36085537
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of Current Methods to Detect Cellular Leucine-Rich Repeat Kinase 2 (LRRK2) Kinase Activity.
    Fernández B; Chittoor-Vinod VG; Kluss JH; Kelly K; Bryant N; Nguyen APT; Bukhari SA; Smith N; Lara Ordóñez AJ; Fdez E; Chartier-Harlin MC; Montine TJ; Wilson MA; Moore DJ; West AB; Cookson MR; Nichols RJ; Hilfiker S
    J Parkinsons Dis; 2022; 12(5):1423-1447. PubMed ID: 35599495
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of phospho-specific Rab protein antibodies to monitor
    Lis P; Burel S; Steger M; Mann M; Brown F; Diez F; Tonelli F; Holton JL; Ho PW; Ho SL; Chou MY; Polinski NK; Martinez TN; Davies P; Alessi DR
    Biochem J; 2018 Jan; 475(1):1-22. PubMed ID: 29127256
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.